B
3.82
0.04 (0.93%)
| Previous Close | 3.78 |
| Open | 3.80 |
| Volume | 483,329 |
| Avg. Volume (3M) | 1,010,968 |
| Market Cap | 217,359,296 |
| Price / Earnings (TTM) | 10.31 |
| Price / Sales | 3.13 |
| Price / Book | 1.73 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 7.27% |
| Operating Margin (TTM) | 77.90% |
| Diluted EPS (TTM) | 0.060 |
| Total Debt/Equity (MRQ) | 15.25% |
| Current Ratio (MRQ) | 9.24 |
| Operating Cash Flow (TTM) | 12.31 M |
| Levered Free Cash Flow (TTM) | 10.10 M |
| Return on Assets (TTM) | -0.42% |
| Return on Equity (TTM) | 4.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Black Diamond Therapeutics, Inc | Bearish | Bearish |
AIStockmoo Score
-1.0
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.00 |
|
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 83.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (Piper Sandler, 135.91%) | Buy |
| Median | 8.50 (122.81%) | |
| Low | 8.00 (Stifel, 109.70%) | Buy |
| Average | 8.50 (122.81%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 4.08 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 18 Nov 2025 | 9.00 (135.91%) | Buy | 3.97 |
| Stifel | 16 Oct 2025 | 8.00 (109.70%) | Buy | 4.18 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Dec 2025 | Announcement | Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM |
| 02 Dec 2025 | Announcement | Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update |
| 06 Nov 2025 | Announcement | Black Diamond Therapeutics to Participate in Upcoming Investor Conferences |
| 06 Nov 2025 | Announcement | Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |